公开(公告)号：US10197559B2

公开(公告)日：2019-02-05

申请号：US14640263

申请日：2015-03-06

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alexander Riedel ,  Peter Schaarschmidt ,  Urban Schmitt ,  Christian Scholz

IPC: C12N9/90 ,  G01N33/53 ,  C07K14/245

Abstract: The invention concerns a fusion polypeptide including several molecules of folding helper polypeptides, including one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to the fusion polypeptide. The invention further concerns an immunoassay and the use of the fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising the fusion polypeptide.

公开(公告)号：US09316642B2

公开(公告)日：2016-04-19

申请号：US14335022

申请日：2014-07-18

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Elke Faatz ,  Peter Schaarschmidt ,  Urban Schmitt ,  Christian Scholz

IPC: A61K39/02 ,  A61K39/00 ,  G01N33/53 ,  G01N33/571 ,  C07K14/20

CPC classification number: G01N33/571 ,  C07K14/20 ,  C07K2319/00 ,  G01N2333/20 ,  G01N2469/20

Abstract: The invention concerns soluble variants of Treponema pallidum antigen 47 (TpN47 antigen) comprising at least domain B, or at least domains A and B, optionally domain D of the complete TpN47 protein molecule with the proviso that all antigens lack domain C (amino acid residues 224 to 351) of TpN47. The Tpn47 antigens can be fused to a chaperone. Moreover, the invention covers DNA encoding the antigens, a method of producing these antigens as well as the use of these antigens in an immunodiagnostic assay for the detection of antibodies against Treponema pallidum in an isolated sample.

Abstract translation: 本发明涉及包含至少结构域B或者至少结构域A和B，完全TpN47蛋白质分子的任选结构域D的梅毒螺旋体抗原47（TpN47抗原）的可溶性变体，条件是所有抗原缺失结构域C（氨基酸残基 224〜351）TpN47。 Tpn47抗原可以融合到伴侣。 此外，本发明涵盖编码抗原的DNA，制备这些抗原的方法以及在免疫诊断测定中使用这些抗原来检测分离样品中针对梅毒螺旋体的抗体。

公开(公告)号：US20150132859A1

公开(公告)日：2015-05-14

申请号：US14334773

申请日：2014-07-18

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Elke Faatz ,  Peter Schaarschmidt ,  Urban Schmitt ,  Christian Scholz

IPC: G01N33/68 ,  C07K14/245 ,  C07K14/28

CPC classification number: G01N33/6854 ,  C07K14/245 ,  C07K14/28 ,  C07K2319/35 ,  G01N33/5306 ,  G01N33/571 ,  G01N2333/20 ,  G01N2333/28 ,  G01N2469/20 ,  G01N2800/26

Abstract: The invention relates to a method for detecting antibodies against the TpN17 antigen of Treponema pallidum in an isolated sample wherein a peptide sequence of Vibrio cholerae lipoprotein 15 (VcLp15) or a partial sequence thereof is used as a reagent for reduction of interference, i.e. for minimizing false positive results. In addition the invention relates to fusion polypeptides comprising a VcLp15 peptide sequence and a chaperone, to their use as an additive in an immunoassay for said reduction of interferences and for minimizing false positive results and to a reagent kit for detecting antibodies against Treponema pallidum antigens in an isolated sample comprising a TpN17 antigen and said VcLp15-chaperone fusion polypeptide.

Abstract translation: 本发明涉及在分离的样品中检测针对梅毒螺旋体的TpN17抗原的抗体的方法，其中使用霍乱弧菌脂蛋白15（VcLp15）或其部分序列的肽序列作为减少干扰的试剂，即最小化 假阳性结果。 此外，本发明涉及包含VcLp15肽序列和伴侣的融合多肽，用于在用于所述减少干扰和最小化假阳性结果的免疫测定中作为添加剂，以及用于检测针对梅毒螺旋体抗原的抗体的试剂盒 包含TpN17抗原和所述VcLp15伴侣融合多肽的分离样品。

公开(公告)号：US20170261498A1

公开(公告)日：2017-09-14

申请号：US14640263

申请日：2015-03-06

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alexander Riedel ,  Peter Schaarschmidt ,  Urban Schmitt ,  Christian Scholz

IPC: G01N33/53 ,  C07K14/245 ,  C12N9/90

CPC classification number: G01N33/5306 ,  C07K14/245 ,  C07K2319/35 ,  C07K2319/735 ,  C12N9/90 ,  C12Y502/01008

Abstract: The invention concerns a fusion polypeptide comprising several molecules of folding helper polypeptides, comprising one multimerization domain, in particular Skp, and at least one molecule of SlyD or SlpA, wherein no further target polypeptide sequences are fused to said fusion polypeptide. The invention further concerns an immunoassay and the use of said fusion polypeptide in an immunoassay for reduction of interferences or minimizing false positive results or for stabilizing proteinaceous assay reagents. Further the invention concerns a reagent kit for use in an immunoassay comprising said fusion polypeptide.

公开(公告)号：US20150079604A1

公开(公告)日：2015-03-19

申请号：US14335022

申请日：2014-07-18

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Elke Faatz ,  Peter Schaarschmidt ,  Urban Schmitt ,  Christian Scholz

IPC: G01N33/571 ,  C07K14/20

CPC classification number: G01N33/571 ,  C07K14/20 ,  C07K2319/00 ,  G01N2333/20 ,  G01N2469/20

Abstract: The invention concerns soluble variants of Treponema pallidum antigen 47 (TpN47 antigen) comprising at least domain B, or at least domains A and B, optionally domain D of the complete TpN47 protein molecule with the proviso that all antigens lack domain C (amino acid residues 224 to 351) of TpN47. The Tpn47 antigens can be fused to a chaperone. Moreover, the invention covers DNA encoding the antigens, a method of producing these antigens as well as the use of these antigens in an immunodiagnostic assay for the detection of antibodies against Treponema pallidum in an isolated sample.

Abstract translation: 本发明涉及包含至少结构域B或者至少结构域A和B，完全TpN47蛋白质分子的任选区域D的梅毒螺旋体抗原47（TpN47抗原）的可溶性变体，条件是所有抗原都缺乏结构域C（氨基酸残基 224〜351）TpN47。 Tpn47抗原可以融合到伴侣。 此外，本发明涵盖编码抗原的DNA，制备这些抗原的方法以及在免疫诊断测定中使用这些抗原来检测分离样品中针对梅毒螺旋体的抗体。

公开(公告)号：US09714949B2

公开(公告)日：2017-07-25

申请号：US14334773

申请日：2014-07-18

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Elke Faatz ,  Peter Schaarschmidt ,  Urban Schmitt ,  Christian Scholz

IPC: G01N33/53 ,  G01N33/68 ,  C07K14/28 ,  G01N33/571 ,  C07K14/245

CPC classification number: G01N33/6854 ,  C07K14/245 ,  C07K14/28 ,  C07K2319/35 ,  G01N33/5306 ,  G01N33/571 ,  G01N2333/20 ,  G01N2333/28 ,  G01N2469/20 ,  G01N2800/26

Abstract: The invention relates to a method for detecting antibodies against the TpN17 antigen of Treponema pallidum in an isolated sample wherein a peptide sequence of Vibrio cholerae lipoprotein 15 (VcLp15) or a partial sequence thereof is used as a reagent for reduction of interference, i.e. for minimizing false positive results. In addition the invention relates to fusion polypeptides comprising a VcLp15 peptide sequence and a chaperone, to their use as an additive in an immunoassay for said reduction of interferences and for minimizing false positive results and to a reagent kit for detecting antibodies against Treponema pallidum antigens in an isolated sample comprising a TpN17 antigen and said VcLp15-chaperone fusion polypeptide.